Good News, Bad News For Novartis' Oral MS Drug, But REMS Could Help
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis' fingolimod, which could become the first oral treatment for relapsing-remitting multiple sclerosis, recently beat Biogen Idec's Avonex in a head-to-head Phase III trial. The bad news for Novartis is that a handful of severe safety signals, spotted in Phase II, recurred in this most recent trial of the drug
You may also be interested in...
Novartis Launches Extavia For Practice In MS Market, Preparing For FTY720
Novartis is launching its interferon beta-1b product Extavia not to be competitive in the multiple sclerosis market so much as to get a sales infrastructure up and running for its late-stage oral MS drug fingolimod (FTY720), Pharmaceuticals CEO Joe Jimenez said during the firm's 2008 year-end earnings call Jan. 28
Novartis Hedges Its Bet On Fingolimod In MS
Submission of backup compound would come three years after filing of initial candidate.
Biogen, Amylin Feel Impact Of Safety Scares; Another Wrinkle With TOUCH
Biogen Idec's landmark risk management program for Tysabri (natalizumab) is paying another dividend for the company: providing management with a credible source of data to reassure investors nervous about the commercial impact of newly reported cases of progressive multifocal leukoencephalopathy (PML) associated with the MS therapy